Emerging drugs for the treatment of soft tissue sarcomas

Bibliography

• CLARK MA, FISHER C, JUDSON I, THOMAS JM: Soft-tissue sarcomas in adults. N. Engl. J. Med. (2005) 353:701-711.
   Google Scholar
• HELMAN LJ, MELTZER P: Mechanisms of sarcoma development: Nat. Rev. Cancer (2003) 3:685-694.
   PubMed Web of Science ®Google Scholar
• CORLESS CL, SCHROEDER A, GRIFFITH D et al.: PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib. J. Clin. Oncol. (2005) 23:5357-5364.
   PubMed Web of Science ®Google Scholar
• DEMATTEO RP, HEINRICH MC, EL-RIFAI WM, DEMETRI G: Clinical management of gastrointestinal stromal tumors: before and after STI-571. Hum. Pathol. (2002) 33:466-477.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VON MM, BLANKE CD et al.: Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. (2002) 347:472-480.
   PubMed Web of Science ®Google Scholar
• GOLD JS, DEMATTEO RP: Combined surgical and molecular therapy: the gastrointestinal stromal tumor model. Ann. Surg. (2006) 244:176-184.
   PubMed Web of Science ®Google Scholar
• NILSSON B, BUMMING P, MEIS-KINDBLOM JM et al.: Gastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era-a population-based study in western Sweden. Cancer (2005) 103:821-829.
   PubMed Web of Science ®Google Scholar
• CORLESS CL, FLETCHER JA, HEINRICH MC: Biology of gastrointestinal stromal tumors. J. Clin. Oncol. (2004) 22:3813-3825.
   PubMed Web of Science ®Google Scholar
• HIROTA S, ISOZAKI K, MORIYAMA Y et al.: Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science (1998) 279:577-580.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, CORLESS CL, DUENSING A et al.: PDGFRA activating mutations in gastrointestinal stromal tumors. Science (2003) 299:708-710.
   PubMed Web of Science ®Google Scholar
• MIETTINEN M, LASOTA J: Gastrointestinal stromal tumors: pathology and prognosis at different sites. Semin. Diagn. Pathol. (2006) 23:70-83.
   PubMed Web of Science ®Google Scholar
• RAUT CP, POSNER M, DESAI J et al.: Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors. J. Clin. Oncol. (2006) 24:2325-2331.
   PubMed Web of Science ®Google Scholar
• RUTKOWSKI P, NOWECKI Z, NYCKOWSKI P et al.: Surgical treatment of patients with initially inoperable and/or metastatic gastrointestinal stromal tumors (GIST) during therapy with imatinib mesylate. J. Surg. Oncol. (2006) 93:304-311.
   PubMed Web of Science ®Google Scholar
• BLAY JY, BONVALOT S, CASALI P et al.: Consensus meeting for the management of gastrointestinal stromal tumors. Report of the GIST Consensus Conference of 20-21 March 2004, under the auspices of ESMO. Ann. Oncol. (2005) 16:566-578.
   PubMed Web of Science ®Google Scholar
• BLANKE CD, DEMETRI GD, VON MEHREN M et al.: Long-term follow-up of a Phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate. ASCO Meeting Abstracts (2006) 24:9528.
   Google Scholar
• ZALCBERG JR, VERWEIJ J, CASALI PG et al.: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur. J. Cancer (2005) 41:1751-1757.
   PubMed Web of Science ®Google Scholar
• DEMETRI GD, VAN OOSTEROM AT, GARRETT CR et al.: Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet (2006) 368:1329-1338.
   PubMed Web of Science ®Google Scholar
• KANTARJIAN H, GILES F, WUNDERLE L et al.: Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N. Engl. J. Med. (2006) 354:2542-2551.
   PubMed Web of Science ®Google Scholar
• REICHARDT P, CASALI PG, BLAY J et al.: A Phase I study of AMN107 alone and in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST). ASCO Meeting Abstracts (2006) 24:9545.
   Google Scholar
• JOENSUU H, DE BRAUD F, COCO P et al.: A Phase II, open-label study of PTK787/ZK222584 in the treatment of metastatic gastrointestinal stromal tumors (GISTs) resistant to imatinib mesylate. ASCO Meeting Abstracts (2006) 24:9531.
   Google Scholar
• BENJAMIN R, SCHÖFFSKI P, HARTMANN JT et al.: Initial results of a multicenter, single-arm Phase II study of AMG706, an oral multikinase inhibitor, for the treatment of advanced imatinib-resistant gastrointestinal stromal tumors (GIST). Connective Tissue Oncology Society 12th Annual Meeting (2006):Abstract.
   Google Scholar
• FLETCHER CD, BERMAN JJ, CORLESS C et al.: Diagnosis of gastrointestinal stromal tumors: a consensus approach. Hum. Pathol. (2002) 33:459-465.
   PubMed Web of Science ®Google Scholar
• DEMATTEO RP, ANTONESCU CR, CHADARAM V et al.: Adjuvant imatinib mesylate in patients with primary high risk gastrointestinal stromal tumor (GIST) following complete resection: safety results from the US Intergroup Phase II trial ACOSOG Z9000. ASCO Meeting Abstracts (2005) 23:9009.
   Google Scholar
• STEWART LA, PARMAR MK, FLETCHER CD et al.: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet (1997) 350:1647-1654.
   PubMed Web of Science ®Google Scholar
• FRUSTACI S, GHERLINZONI F, DE PA et al.: Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J. Clin. Oncol. (2001) 19:1238-1247.
   PubMed Web of Science ®Google Scholar
• VAN GLABBEKE M, VAN OOSTEROM AT, OOSTERHUIS JW et al.: Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-a European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J. Clin. Oncol. (1999) 17:150-157.
   PubMed Web of Science ®Google Scholar
• EDMONSON JH, RYAN LM, BLUM RH et al.: Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J. Clin. Oncol. (1993) 11:1269-1275.
   PubMed Web of Science ®Google Scholar
• SANTORO A, TURSZ T, MOURIDSEN H et al.: Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J. Clin. Oncol. (1995) 13:1537-1545.
   PubMed Web of Science ®Google Scholar
• CASALI P, PASTORINO U, AZZARELLI A et al.: Perspectives on anthracyclines plus ifosfamide in advanced soft tissue sarcomas. Cancer Chemother. Pharmacol. (1993) 31(Suppl. 2):S228-S232.
   PubMed Web of Science ®Google Scholar
• WIKLUND T, HUUHTANEN R, BLOMQVIST C et al.: The importance of a multidisciplinary group in the treatment of soft tissue sarcomas. Eur. J. Cancer (1996) 32A:269-273.
   PubMed Web of Science ®Google Scholar
• RYDHOLM A: Improving the management of soft tissue sarcoma. Diagnosis and treatment should be given in specialist centres. Br. Med. J. (1998) 317:93-94.
   PubMed Web of Science ®Google Scholar
• RAY-COQUARD I, THIESSE P, RANCHERE-VINCE D et al.: Conformity to clinical practice guidelines, multidisciplinary management and outcome of treatment for soft tissue sarcomas. Ann. Oncol. (2004) 15:307-315.
   PubMed Web of Science ®Google Scholar
• PELLEGRINI F, BUDMAN DR: Review: tubulin function, action of antitubulin drugs, and new drug development. Cancer Invest. (2005) 23:264-273.
   PubMed Web of Science ®Google Scholar
• GOODIN S, KANE MP, RUBIN EH: Epothilones: mechanism of action and biologic activity. J. Clin. Oncol. (2004) 22:2015-2025.
   PubMed Web of Science ®Google Scholar
• SVANCAROVA L, BLAY JY, JUDSON IR et al.: Gemcitabine in advanced adult soft-tissue sarcomas. A Phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer (2002) 38:556-559.
   PubMed Web of Science ®Google Scholar
• EDMONSON JH, EBBERT LP, NASCIMENTO AG, JUNG SH, MCGAW H, GERSTNER JB: Phase II study of docetaxel in advanced soft tissue sarcomas. Am. J. Clin. Oncol. (1996) 19:574-576.
   Google Scholar
• VAN HOESEL QG, VERWEIJ J, CATIMEL G et al.: Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann. Oncol.. (1994) 5:539-542.
   PubMed Web of Science ®Google Scholar
• CASPER ES, WALTZMAN RJ, SCHWARTZ GK et al.: Phase II trial of paclitaxel in patients with soft-tissue sarcoma. Cancer Invest. (1998) 16:442-446.
   PubMed Web of Science ®Google Scholar
• PATEL SR, JENKINS J, PAPADOPOLOUS N et al.: Pilot study of vitaxin-an angiogenesis inhibitor-in patients with advanced leiomyosarcomas. Cancer (2001) 92:1347-1348.
   PubMed Web of Science ®Google Scholar
• FATA F, O’REILLY E, ILSON D et al.: Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer (1999) 86:2034-2037.
   PubMed Web of Science ®Google Scholar
• SKUBITZ KM, HADDAD PA: Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer (2005) 104:361-366.
   PubMed Web of Science ®Google Scholar
• HENSLEY ML, MAKI R, VENKATRAMAN E et al.: Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a Phase II trial. J. Clin. Oncol. (2002) 20:2824-2831.
   PubMed Web of Science ®Google Scholar
• BAY JO, RAY-COQUARD I, FAYETTE J et al.: Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int. J. Cancer (2006) 119:706-711.
   PubMed Web of Science ®Google Scholar
• DELALOGE S, YOVINE A, TAAMMA A et al.: Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients-preliminary evidence of activity. J. Clin. Oncol. (2001) 19:1248-1255.
   PubMed Web of Science ®Google Scholar
• YOVINE A, RIOFRIO M, BLAY JY et al.: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. (2004) 22:890-899.
   PubMed Web of Science ®Google Scholar
• LE CESNE A, BLAY JY, JUDSON I et al.: Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J. Clin. Oncol. (2005) 23:576-584.
   PubMed Web of Science ®Google Scholar
• GARCIA-CARBONERO R, SUPKO JG, MANOLA J et al.: Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J. Clin. Oncol. (2004) 22:1480-1490.
   PubMed Web of Science ®Google Scholar
• GARCIA-CARBONERO R, SUPKO JG, MAKI RG et al.: Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter Phase II and pharmacokinetic study. J. Clin. Oncol. (2005) 23:5484-5492.
   PubMed Web of Science ®Google Scholar
• SAMUELS BL, RUSHING D, CHAWLA SP et al.: Randomized Phase II study of trabectedin (ET-743) given by two different dosing schedules in patients (pts) with leiomyosarcomas (LMS) or liposarcomas (LPS) refractory to conventional doxorubicin and ifosfamide chemotherapy. ASCO Meeting Abstracts (2004) 22:9000.
   Google Scholar
• RYAN DP, PUCHALSKI T, SUPKO JG et al.: A Phase II and pharmacokinetic study of ecteinascidin 743 in patients with gastrointestinal stromal tumors. Oncologist (2002) 7:531-538.
   PubMed Web of Science ®Google Scholar
• BLAY JY, BERTHAUD P, PEROL D et al.: Continuous versus intermittent imatinib treatment in advanced GIST after one year: a prospective randomized Phase III trial of the French Sarcoma Group. ASCO Meeting Abstracts (2004) 22:9006.
   Google Scholar
• LOCKHART AC, HOWARD M, HANDE KR et al.: A Phase I dose-escalation and pharmacokinetic study of brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin. Cancer Res. (2004) 10:468-475.
   PubMed Web of Science ®Google Scholar
• LEAHY M, RAY-COQUARD I, VERWEIJ J et al.: Brostallicin, an agent with potential activity in metastatic soft tissue sarcoma: a Phase II study from the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer (2006) 43(2):308-315.
   PubMed Web of Science ®Google Scholar
• JOENSUU H, ROBERTS PJ, SARLOMO-RIKALA M et al.: Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N. Engl. J. Med. (2001) 344:1052-1056.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEROM AT, JUDSON I, VERWEIJ J et al.: Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I study. Lancet (2001) 358:1421-1423.
   PubMed Web of Science ®Google Scholar
• VERWEIJ J, CASALI PG, ZALCBERG J et al.: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet (2004) 364:1127-1134.
   PubMed Web of Science ®Google Scholar
• BLAY JY, GEORGE S, CASALI P et al.: Clinical benefit of continuous daily dosing of Sunitinib in patients (pts) with advanced gastrointestinal stromal tumors (GIST). Ann. Oncol.. (2006) 17:ix161-ix170.
   Google Scholar
• SCHITTENHELM MM, SHIRAGA S, SCHROEDER A et al.: Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies. Cancer Res. (2006) 66:473-481.
   PubMed Web of Science ®Google Scholar
• MORGAN JA, GARRETT CR, SCHUTTE HJ et al.: Sunitinib for patients (pts) with advanced imatinib (IM)-refractory GIST: early results from a ‘treatment-use’ trial. ASCO Meeting Abstracts (2006) 24:9540.
   Google Scholar
• POLVERINO A, COXON A, STARNES C et al.: AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts. Cancer Res. (2006) 66:8715-8721.
   PubMed Web of Science ®Google Scholar
• DEBIEC-RYCHTER M, COOLS J, DUMEZ H et al.: Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology (2005) 128:270-279.
   PubMed Web of Science ®Google Scholar
• WEISBERG E, WRIGHT RD, JIANG J et al.: Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Gastroenterology (2006) 131(6):1734-1742.
   PubMed Web of Science ®Google Scholar
• REICHARDT P, PINK D, LINDNER T et al.: A Phase I/II trial of the oral PKC-inhibitor PKC412 (PKC) in combination with imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM. ASCO Meeting Abstracts (2005) 23:3016.
   Google Scholar
• PRENEN H, DEWAELE B, COOLS J et al.: In vitro activity of the multi-targeted kinase inhibitor sorafenib (BAY43-9006) against gastrointestinal stromal tumor (GIST) mutants refractory to imatinib mesylate. Eur. J. Cancer Suppl. (2006) 4:171.
   Web of Science ®Google Scholar
• CHAWLA SP, TOLCHER AW, STADDON AP et al.: Updated results of a Phase II trial of AP23573, a novel mTOR inhibitor, in patients (pts) with advanced soft tissue or bone sarcomas. ASCO Meeting Abstracts (2006) 24:9505.
   Google Scholar
• VAN GLABEKKE M, VERWEIJ J, JUDSON I, NIELSEN OS: Progression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomas. Eur. J. Cancer (2002) 38:543-549.
   PubMed Web of Science ®Google Scholar
• MONDESIRE WH, JIAN W, ZHANG H et al.: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clin. Cancer Res. (2004) 10:7031-7042.
   PubMed Web of Science ®Google Scholar
• VAN OOSTEROM A, REICHARDT P, BLAY JY et al.: A Phase I/II trial of the oral mTOR-inhibitor everolimus (E) and imatinib mesylate (IM) in patients (pts) with gastrointestinal stromal tumor (GIST) refractory to IM: study update. ASCO Meeting Abstracts (2005) 23:9033.
   Google Scholar
• KUMAR S, WITZIG TE, RAJKUMAR SV: Thalidomid: current role in the treatment of non-plasma cell malignancies. J. Clin. Oncol. (2004) 22:2477-2488.
   PubMed Web of Science ®Google Scholar
• D’ADAMO DR, ANDERSON SE, ALBRITTON K et al.: Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J. Clin. Oncol. (2005) 23:7135-7142.
   PubMed Web of Science ®Google Scholar
• HURWITZ H, DOWLATI A, SAVAGE S et al.: Safety, tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. ASCO Meeting Abstracts (2005) 23:3012.
   Google Scholar
• BAKER LH, DEMETRI GD, MENDELSON DS et al.: A randomized Phase II study of the thrombospondin-mimetic peptide ABT-510 in patients with advanced soft tissue sarcoma (STS). J. Clin. Oncol. (Meeting Abstracts) (2005) 23:9013.
   Google Scholar
• YI-SHIN KD, TIMMINS P, BLANK SV et al.: Phase II trial of thalidomide for advanced and recurrent gynecologic sarcoma: a brief communication from the New York Phase II consortium. Gynecol. Oncol. (2006) 100:160-165.
   Google Scholar
• BISSETT D, O’BYRNE KJ, VON PAWEL J et al.: Phase III study of matrix metalloproteinase inhibitor prinomastat in non-small-cell lung cancer. J. Clin. Oncol. (2005) 23:842-849.
   PubMed Web of Science ®Google Scholar
• LEIGHL NB, PAZ-ARES L, DOUILLARD JY et al.: Randomized Phase III study of matrix metalloproteinase inhibitor BMS-275291 in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: National Cancer Institute of Canada-Clinical Trials Group Study BR.18. J. Clin. Oncol. (2005) 23:2831-2839.
   PubMed Web of Science ®Google Scholar
• MOORE MJ, HAMM J, DANCEY J et al.: Comparison of gemcitabine versus the matrix metalloproteinase inhibitor BAY 12-9566 in patients with advanced or metastatic adenocarcinoma of the pancreas: a Phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J. Clin. Oncol. (2003) 21:3296-302.
   PubMed Web of Science ®Google Scholar
• SYED S, TAKIMOTO C, HIDALGO M et al.: A Phase I and pharmacokinetic study of Col-3 (Metastat), an oral tetracycline derivative with potent matrix metalloproteinase and antitumor properties. Clin. Cancer Res. (2004) 10:6512-6521.
   PubMed Web of Science ®Google Scholar
• DEZUBE BJ, KROWN SE, LEE JY, BAUER KS, ABOULAFIA DM: Randomized Phase II trial of matrix metalloproteinase inhibitor COL-3 in AIDS-related Kaposi’s sarcoma: an AIDS Malignancy Consortium Study. J. Clin. Oncol. (2006) 24:1389-1394.
   PubMed Web of Science ®Google Scholar
• SATO O, WADA T, KAWAI A Y et al.: Expression of epidermal growth factor receptor, ERBB2 and KIT in adult soft tissue sarcomas: a clinicopathologic study of 281 cases. Cancer (2005) 103:1881-1890.
   PubMed Web of Science ®Google Scholar
• THOMAS AL, MORGAN B, HORSFIELD MA et al.: Phase I study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of PTK787/ZK 222584 administered twice daily in patients with advanced cancer. J. Clin. Oncol. (2005) 23:4162-4171.
   PubMed Web of Science ®Google Scholar
• BLAY J, LE CA, WHELAN J et al.: Gefitinib in second line treatment of metastatic or locally advanced synovial sarcoma expressing HER1: a Phase II trial of EORTC Soft Tissue and Bone Sarcoma Group. ASCO Meeting Abstracts (2006) 24:9517.
   Google Scholar
• ALBRITTON KH, RANKIN C, COFFIN CM et al.: Phase II study of erlotinib in metastatic or unresectable malignant peripheral nerve sheath tumors (MPNST). ASCO Meeting Abstracts (2006) 24:9518.
   Google Scholar
• SCOTLANDI K, MANARA MC, HATTINGER CM et al.: Prognostic and therapeutic relevance of HER2 expression in osteosarcoma and Ewing’s sarcoma. Eur. J. Cancer (2005) 41:1349-1361.
   PubMed Web of Science ®Google Scholar
• GORLICK R, HUVOS AG, HELLER G et al.: Expression of HER2/erbB-2 correlates with survival in osteosarcoma. J. Clin. Oncol. (1999) 17:2781-2788.
   PubMed Web of Science ®Google Scholar
• THOMAS DG, GIORDANO TJ, SANDERS D, BIERMANN JS, BAKER L: Absence of HER2/neu gene expression in osteosarcoma and skeletal Ewing’s sarcoma. Clin. Cancer Res. (2002) 8:788-793.
   Google Scholar
• NUCIFORO PG, PELLEGRINI C, FASANI R et al.: Molecular and immunohistochemical analysis of HER2/neu oncogene in synovial sarcoma. Hum. Pathol. (2003) 34:639-645.
   PubMed Web of Science ®Google Scholar
• LEITAO MM, SOSLOW RA, NONAKA D et al.: Tissue microarray immunohistochemical expression of estrogen, progesterone, and androgen receptors in uterine leiomyomata and leiomyosarcoma. Cancer (2004) 101:1455-1462.
   PubMed Web of Science ®Google Scholar
• PINK D, LINDNER T, MROZEK A et al.: Harm or benefit of hormonal treatment in metastatic low-grade endometrial stromal sarcoma: single center experience with 10 cases and review of the literature. Gynecol. Oncol. (2006) 101:464-469.
   Google Scholar
• FAYETTE J, RAY-COQUARD I, BOMPAS E et al.: Aromatase inhibitors (AI) are highly effective in uterine sarcomas (US) expressing estrogen receptors. ASCO Meeting Abstracts (2006) 24:9576.
   Google Scholar
• LANARI A: Effect of progesterone on desmoid tumors (aggressive fibromatosis). N. Engl. J. Med. (1983) 309:1523.
   PubMed Web of Science ®Google Scholar
• WILCKEN N, TATTERSALL MH: Endocrine therapy for desmoid tumors. Cancer (1991) 68:1384-1388.
   PubMed Web of Science ®Google Scholar
• DEYRUP AT, TRETIAKOVA M, MONTAG AG: Estrogen receptor-beta expression in extraabdominal fibromatoses: an analysis of 40 cases. Cancer (2006) 106:208-213.
   PubMed Web of Science ®Google Scholar
• SHERMAN ML, RYAN C, BLACKSTEIN M et al.: Phase I/2 study of STA-4783, a novel heat shock protein 70 (hsp70) inducer, in combination with paclitaxel in patients with soft tissue sarcomas (STS). J. Clin. Oncol. (Meeting Abstracts) (2005) 23:9069.
   Google Scholar
• GREM JL, MORRISON G, GUO XD et al.: Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors. J. Clin. Oncol. (2005) 23:1885-1893.
   PubMed Web of Science ®Google Scholar
• RAMANATHAN RK, TRUMP DL, EISEMAN JL et al.: Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17- demethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers. Clin. Cancer Res. (2005) 11:3385-3391.
   Google Scholar
• DEMETRI GD, GEORGE S, MORGAN JA et al.: Overcoming resistance to tyrosine kinase inhibitors (TKIs) through inhibition of heat shock protein 90 (Hsp90) chaperone function in patients with metastatic GIST: results of a Phase I trial of IPI504, a water-soluble Hsp90 inhibitor. Eur. J. Cancer Suppl. (2006) 4:173.
   Google Scholar
• LENNARTSSON J, JELACIC T, LINNEKIN D, SHIVAKRUPA R: Normal and oncogenic forms of the receptor tyrosine kinase kit. Stem Cells (2005) 23:16-43.
   PubMed Web of Science ®Google Scholar
• PIETRAS K, SJOBLOM T, RUBIN K, HELDIN CH, OSTMAN A: PDGF receptors as cancer drug targets. Cancer Cell (2003) 3:439-443.
   PubMed Web of Science ®Google Scholar
• DIBB NJ, DILWORTH SM, MOL CD: Switching on kinases: oncogenic activation of BRAF and the PDGFR family. Nat. Rev. Cancer (2004) 4:718-727.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, CORLESS CL, DEMETRI GD et al.: Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J. Clin. Oncol. (2003) 21:4342-4349.
   PubMed Web of Science ®Google Scholar
• HEINRICH MC, MAKI RG, CORLESS CL et al.: Sunitinib (SU) response in imatinib-resistant (IM-R) GIST correlates with KIT and PDGFRA mutation status. ASCO Meeting Abstracts (2006) 24:9502.
   Google Scholar
• BIEC-RYCHTER M, SCIOT R, LE CA et al.: KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours. Eur. J. Cancer (2006) 42:1093-103.
   PubMed Web of Science ®Google Scholar
• PILOTTI S, DELLA TG, LAVARINO C et al.: Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. J. Pathol. (1998) 185:188-190.
   Google Scholar
• VASSILEV LT, VU BT, GRAVES B et al.: In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 303:844-848.
   PubMed Web of Science ®Google Scholar
• SONI R, MULLER L, FURET P et al.: Inhibition of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine natural product. Biochem. Biophys. Res. Commun. (2000) 275:877-884.
   Google Scholar
• SABATINI DM: mTOR and cancer: insights into a complex relationship. Nat. Rev. Cancer (2006) 6:729-734.
   PubMed Web of Science ®Google Scholar
• HIDALGO M, BUCKNER JC, ERLICHMAN C et al.: A Phase I and pharmacokinetic study of temsirolimus (CCI-779) administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin. Cancer Res. (2006) 12:5755-5763.
   PubMed Web of Science ®Google Scholar
• OLSSON AK, DIMBERG A, KREUGER J, CLAESSON-WELSH L: VEGF receptor signalling – in control of vascular function. Nat. Rev. Mol. Cell Biol. (2006) 7:359-371.
   Google Scholar
• KERBEL RS: Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science (2006) 312:1171-1175.
   PubMed Web of Science ®Google Scholar
• JAKOB C, STERZ J, ZAVRSKI I et al.: Angiogenesis in multiple myeloma. Eur. J. Cancer (2006) 42:1581-1590.
   PubMed Web of Science ®Google Scholar
• MOTZER RJ, HUTSON TE, TOMCZAK P et al.: Phase III randomized trial of sunitinib malate (SU11248) versus interferon-alfa (IFN-{alpha}) as first-line systemic therapy for patients with metastatic renal cell carcinoma (mRCC). ASCO Meeting Abstracts (2006) 24:LBA3.
   Google Scholar
• HURWITZ H, FEHRENBACHER L, NOVOTNY W et al.: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. (2004) 350:2335-2342.
   PubMed Web of Science ®Google Scholar
• YANG JC, HAWORTH L, SHERRY RM et al.: A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. (2003) 349:427-434.
   PubMed Web of Science ®Google Scholar
• VOLPERT OV, ZAICHUK T, ZHOU W et al.: Inducer-stimulated Fas targets activated endothelium for destruction by anti-angiogenic thrombospondin-1 and pigment epithelium-derived factor. Nat. Med. (2002) 8:349-357.
   Google Scholar
• POTTI A, GANTI AK, FOSTER H et al.: Immunohistochemical detection of HER-2/neu, c-kit (CD117) and vascular endothelial growth factor (VEGF) overexpression in soft tissue sarcomas. Anticancer Res. (2004) 24:333-337.
   PubMed Web of Science ®Google Scholar
• YUDOH K, KANAMORI M, OHMORI K, YASUDA T, AOKI M, KIMURA T: Concentration of vascular endothelial growth factor in the tumour tissue as a prognostic factor of soft tissue sarcomas. Br. J. Cancer (2001) 84:1610-1615.
   PubMed Web of Science ®Google Scholar
• WEST CC, BROWN NJ, MANGHAM DC, GRIMER RJ, REED MW: Microvessel density does not predict outcome in high grade soft tissue sarcoma. Eur. J. Surg. Oncol. (2005) 31:1198-205.
   Google Scholar
• YOON SS, SEGAL NH, OLSHEN AB, BRENNAN MF, SINGER S: Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann. Oncol. (2004) 15:1261-1266.
   PubMed Web of Science ®Google Scholar
• ZHANG L, HANNAY JA, LIU J et al.: Vascular endothelial growth factor overexpression by soft tissue sarcoma cells: implications for tumor growth, metastasis, and chemoresistance. Cancer Res. (2006) 66:8770-8778.
   PubMed Web of Science ®Google Scholar
• ZHANG L, YU D, HU M et al.: Wild-type p53 suppresses angiogenesis in human leiomyosarcoma and synovial sarcoma by transcriptional suppression of vascular endothelial growth factor expression. Cancer Res. (2000) 60:3655-3661.
   PubMed Web of Science ®Google Scholar
• DALAL S, BERRY AM, CULLINANE CJ et al.: Vascular endothelial growth factor: a therapeutic target for tumors of the Ewing’s sarcoma family. Clin. Cancer Res. (2005) 11:2364-2378.
   Google Scholar
• GUAN H, ZHOU Z, WANG H, JIA SF, LIU W, KLEINERMAN ES: A small interfering RNA targeting vascular endothelial growth factor inhibits Ewing’s sarcoma growth in a xenograft mouse model. Clin. Cancer Res. (2005) 11:2662-2669.
   PubMed Web of Science ®Google Scholar
• FUCHS B, INWARDS CY, JANKNECHT R: Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing’s sarcoma. Clin. Cancer Res. (2004) 10:1344-1353.
   Google Scholar
• MURRAY GI, DUNCAN ME, O’NEIL P, MELVIN WT, FOTHERGILL JE: Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. (1996) 2:461-462.
   PubMed Web of Science ®Google Scholar
• OVERALL CM, KLEIFELD O: Tumour microenvironment – opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer (2006) 6:227-239.
   PubMed Web of Science ®Google Scholar
• WHITESELL L, LINDQUIST SL: HSP90 and the chaperoning of cancer. Nat. Rev. Cancer (2005) 5:761-772.
   PubMed Web of Science ®Google Scholar
• CALDERWOOD SK, THERIAULT JR, GONG J: Message in a bottle: role of the 70-kDa heat shock protein family in anti-tumor immunity. Eur. J. Immunol. (2005) 35:2518-2527.
   Web of Science ®Google Scholar
• OPPERMANN H, LEVINSON W, BISHOP JM: A cellular protein that associates with the transforming protein of Rous sarcoma virus is also a heat-shock protein. Proc. Natl. Acad. Sci. USA (1981) 78:1067-1071.
   Google Scholar
• TERRY J, LUBIENIECKA JM, KWAN W, LIU S, NIELSEN TO: Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin prevents synovial sarcoma proliferation via apoptosis in in vitro models. Clin. Cancer Res. (2005) 11:5631-5638.
   PubMed Web of Science ®Google Scholar
• MULTHOFF G, BOTZLER C, WIESNET M, EISSNER G, ISSELS R: CD3- large granular lymphocytes recognize a heat-inducible immunogenic determinant associated with the 72-kD heat shock protein on human sarcoma cells. Blood (1995) 86:1374-1382.
   PubMed Web of Science ®Google Scholar
• BOTZLER C, KOLB HJ, ISSELS RD, MULTHOFF G: Noncytotoxic alkyl-lysophospholipid treatment increases sensitivity of leukemic K562 cells to lysis by natural killer (NK) cells. Int. J. Cancer (1996) 65:633-638.
   PubMed Web of Science ®Google Scholar
• MULTHOFF G, BOTZLER C, JENNEN L, SCHMIDT J, ELLWART J, ISSELS R: Heat shock protein 72 on tumor cells: a recognition structure for natural killer cells. J. Immunol. (1997) 158:4341-4350.
   Google Scholar